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Abstract:  
Raman micro-spectroscopy is a non-invasive analytical tool, whose potential in cellular 
analysis and monitoring drug mechanisms of action has already been demonstrated, and 
which can potentially be used in pre-clinical and clinical applications for the prediction of 
chemotherapeutic efficacy. To further investigate such potential clinical application, it is 
important to demonstrate its capability to differentiate drug mechanisms of action and cellular 
resistances. Using the example of Doxorubicin (DOX), in this study, it was used to probe the 
cellular uptake, signatures of chemical binding and subsequent cellular responses, of the 
chemotherapeutic drug in two lung cancer cell lines, A549 and Calu-1. Multivariate statistical 
analysis was used to elucidate the spectroscopic signatures associated with DOX uptake and 
subcellular interaction. Biomarkers related to DNA damage and repair, and mechanisms 
leading to apoptosis were also measured and correlated to Raman spectral profiles. Results 
confirm the potential of Raman spectroscopic profiling to elucidate both drug kinetics and 
pharmacodynamics and differentiate cellular drug resistance associated with different 
subcellular accumulation rates and subsequent cellular response to DNA damage, pointing 
towards a better understanding of drug resistance for personalised targeted treatment. 
 
 
 
Abstract Figure: 
 
 
 
DNA damage and repair measured by Raman micro-spectroscopy and Mean Fluorescence of 
γH2AX after DOX exposure. Intensities expressed on percentage according to the maximum 
value for both cell lines. 
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1. Introduction: 
In the continued search for more effective chemotherapeutic treatments, there is a 
concomitant need for the development of improved screening techniques, particularly at the 
pre-clinical stage. Development of a new drug product from start to end is a very long 
process, taking on average 12 years, and costing, on average, $1.2 billion per product [1-3]. 
EU Directive-2010/63/EU on the replacement, reduction and refinement of animal 
experimentation has prioritised the development of rapid, cost effective in vitro techniques 
for toxicological and pharmaceutical screening applications, amongst others. 
High Throughput Screening techniques allow for the evaluation of multiple biochemical and 
morphological parameters in cells based on image analysis of morphological changes or 
monitoring multiple fluorescently labelled species/processes in a cellular population (Flow 
Cytometry) or at a subcellular level (Confocal Microscopy) [4]. Notably, however, such 
screening and analytical techniques are phenomenological rather than molecularly specific 
and thus are limited in their ability to elucidate the underlying mechanisms. Alternative, high 
content assaying techniques for in vitro cytological screening and analysis are therefore 
desirable. 
Furthermore, despite the increased understanding of cancer biology and cellular drug 
mechanisms, all patients have a varied response to chemotherapeutic treatment and can 
develop adverse reactions and resistance to many approved drugs on the market. As an 
example, lung cancer remains the most common cause of cancer death worldwide [5, 6], 
despite the recent significant process in treatment and prevention [7, 8] and chemotherapeutic 
resistance is a major cause of treatment failure [9]. This highlights the need for personalised 
predictive testing to identify and characterise clinical biomarkers related either to the drug 
effects or to patient resistance. The development of an analytical tool for prediction of 
chemosensitivity, either in pre-clinical or diagnostic stages, is of great importance in order to 
adapt cancer treatment for each individual patient [10, 11]. 
Raman micro-spectroscopy is an analytical technique whose potential for biological analysis 
has already been demonstrated [12-14]. Therefore, it can be considered as a potential 
candidate for exploring pre-clinical drug development and clinical applications, by 
identifying signatures of drug mechanisms of interaction and even of cell dependent drug at a 
subcellular level. 
As a proof of concept, a commercialy available drug Doxorubicin (DOX) is used in this study 
to demonstrate the potential of  Raman micro-spectroscopy to monitor the uptake, interaction 
mechanisms and subsequent cellular responses, for pre-clinicial screening, as well as to 
differentiate the responses of two different cell lines, identifying markers of drug resistance, 
and therefore its potential as a companion diagnostic tool for personalized medicine. DOX is 
an anthracycline widely used in chemotherapy for the treatment of various human cancers 
and aggressive tumours [15, 16], despite its serious side effects, principally cardiotoxicity, 
and a not fully understood mechanism of action [17-19]. In previous in vitro reports, different 
relative contributions of subcellular processes have been observed, depending on cell line, 
[20] including ROS production, intercalation between nucleic base pairs and Topoisomerase 
II inhibition, blocking of DNA replication [17, 21] and induction of DNA double stand 
breaks (DSB) by nucleosome turnover increase, leading to cellular apoptosis [22-24]. DSB 
induce a DNA damage response (DDR) which can be visualised locally as an accumulation 
of repair proteins, known as nuclear foci [25] and chromatin modification acting as an 
adaptor attracting and localizing retention of DNA repair proteins. The cellular DNA damage 
and repair capacity influences the effects of an anticancer drug [26] and can be used as a 
biomarker of chemotherapeutic efficacy and resistance [27]. Moreover, resistance to 
apoptosis, programmed cell death, by either increase of apoptosis inhibitor protein or, higher 
tolerance to DNA damage or DNA repair, is associated with chemoresistance [18] and a poor 
clinical prognosis in cancer therapy and can be used as a marker for individualised treatment 
[28]. 
The present study expands the provious work exploring the use of Raman micro-spectroscopy 
to monitor DOX effects and cellular responses in vitro [17, 20] to a comparison of the uptake 
kinetics and responses of two different histological subtype cell lines, A549 and Calu-1. In 
order to extract biological information contained in Raman spectra, multivariate data analysis 
consising of Principal Component Analysis (PCA), Partial Last Square Regression (PLSR) 
and Independent Component Analysis (ICA) is used. Raman investigations are supported by 
cytotoxicity assays;  apoptotic marker of nuclear condensation, specific anti-apoptotic protein 
(bcl-2) and DNA damage and repair by measurement of γH2AX, to identify different DOX 
sensitivities, monitor cellular uptake and response mechanisms. 
 
 
 
2. Materials and methods:  
2.1. Materials: 
A549 human lung adenocarcinoma cells with the alveolar type II phenotype were obtained 
from ATTC (Manassas, VA, USA) and Calu-1 human lung epidermoid carcinoma cell line, 
was kindly provided by Dr. Josep Sulé-Suso, Institute for Science & Technology in 
Medicine, Keele University, Guy Hilton Research Centre UK and Cancer Centre, Royal 
Stoke University Hospital, University Hospitals of North Midlands, UK.  
A Doxorubicin stock solution of concentration 17.25 mM was prepared by dilution of 
Doxorubicin hydrochloride
®
 powder (Sigma Life Sciences, Ireland) in1mL sterile water. 
Alamar blue (AB) (10X ready to use solution) and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide (MTT) were obtained from Sigma Aldrich, Ireland.  
For cytotoxicity assays, an AB/MTT solution, 1.5mL of AB and 3 mL of MTT stock solution 
(2.5mg/mL, 25mg MTT/10mL PBS) in 30mL of fresh medium was prepared prior to 
performing the assays. 
Nucred
®
 live 647 Ready Probes
®
 Reagent, used to image the cellular nuclear condensation, 
the fixation/permeabilization kit, BD Cytofix/Cytoperm (BD 554714), and FITC Mouse Anti-
Human bcl-2 set with an IgG1 isotype control (BD 556357) was purchased from 
BioSciences, Ireland. 
γH2AX reagents, Alexa Fluor® 647 anti H2AX phospho (Ser 139) and Alexa Fluor® 647 
mouse IgG1 isotype control (ICFC), Biolegends, were supplied through Medical Supply 
Company Ltd., Ireland.  
 
2.2. Cell culture 
A549 cells were cultured in DMEM-F12 with 10% foetal bovine serum (FBS) and Calu-1 
cells in RPMI with 10% FBS, both at 37°C in a humidified atmosphere containing 5% CO2 
and cells were split every two days to maintain ~60% confluency. 
For Cytotoxicity assays, Confocal Laser Scanning Fluorescence Microscopy (CLSM) and 
Raman micro spectroscopic analysis, the cell number was determined using a Beckman 
Coulter Particle Count and Size Analysis
®
 Z2 Cell Counter. 
 
 
 
2.3. Cytotoxicity assays: 
AB and MTT assays were performed in 96 well plates and a total number of 1x10
5
 cells 
(4x10
3 
cells/mL), 1 x 10
4 
(4x10
2 
cells/mL) and 5x10
3
cells (2x10
2 
cells/mL), respectively for 
0-24hrs, 48hrs and 72hrs, with three replicate plates of each. After 24 hrs incubation, plates 
were washed with phosphate buffered saline solution (PBS) and DOX was added in a 
concentration range from 0 µM (as a control) to 50 µM. 
AB and MTT assays were both measured with a Cytotox SpectraMax
®
M3 plate reader using 
Soft Max
®
 Pro 6.2.2 software. After 6, 24, 48 and 72 hrs incubation in DOX, plates were 
washed with PBS and 100µL of AB/MTT solution were added to each well. Plates were then 
incubated for 3 hours and AB fluorescence was measured first in the plate reader using 540 
nm excitation and 595nm emission, then the medium was removed, the plates were washed 
with PBS and 100µL of DMSO (Dimethyl sulfoxide) were added in each well.  
MTT absorbance was read at 570nm.  
All cytotoxicity assays were made in triplicate and repeated three times and viability data was 
fitted by a four parameter Hill equation analysis using SigmaPlot 10.0, to yield values of the 
mean inhibitory concentration, IC50. 
 
2.4. Raman micro-spectroscopy: 
 
Cells (~ 1x 10
4
/window) were seeded and incubated on CaF2 windows (Crystan Ltd, UK) for 
24 hrs for both control and exposure to DOX. The medium was then removed and samples 
were rinsed twice with sterile PBS and covered with DOX at each corresponding IC50 
inhibitory concentration, adjusted to the cell number [29]. After each incubation period, 2, 6, 
12, 24, 48 and 72 hrs, cells were washed twice with sterile PBS and fixed in formalin (4%, 
15min). 
A Horiba Jobin-Yvon LabRAM HR800 spectrometer with a 785nm, 300mW diode laser as 
source, Peltier cooled 16-bit CCD, 300 lines/mm grating and 100 μm confocal hole, was used 
for this work. Spectra were acquired in the range from 400 cm
-1
 to 1800 cm
-1
 using a x100 
objective (LCPlanN, Olympus), in dry conditions, for 30s two times, from three cell 
locations: cytoplasm, nucleus and nucleolus, visible under white light illumination. A final 
data set of 30 points per cell location for each time point, 2, 6, 12, 24, 48 and 72hrs was 
produced after DOX exposure and for control cells, for each cell line, amounting to a total of 
over 210 cells per cell line, corresponding to a total data set of 1260 spectra. 
2.5. Data analysis:  
 
Raman spectral pre-processing and analysis were performed in Matlab2013 using algorithms 
developed in house. Prior to analysis, background was subtracted using a NCLS (non-
negatively constrained least squares) algorithm and spectra were smoothed (Savitsky-Golay 
filter 3th order, 11 points), baseline corrected (fifth order polynomial) and vector normalised. 
PCA was employed as an unsupervised multivariate approach to analyse data and the effects 
of doxorubicin in each cell localisation. The order of the PCs denotes their importance to the 
dataset and PC1 describes the highest amount of variation [13, 17]. 
PLSR, a statistical regression technique which reduces the dimensionality of the data and 
correlates information, here represented by the Raman spectra, to time evolution, was 
employed to track the temporal dependent evolution of the spectral signatures in the 
subcellular regions [13, 30]. The percentage of variance explained as a function of the 
number of components was calculated using 10-fold cross validation and from a plot of the 
percent of variance explained function of number of components, the majority percentage of 
variance (above 90%) was found to be explained by the first 3 components. The regression 
coefficients obtained by PLSR of Raman data regressed against time were plotted and 
analysed. As a function of frequency, the co-efficients illustrate the spectral features which 
are influenced by the intracellular interaction of the DOX and the resulting metabolic 
changes. 
ICA was also employed as an extension to PCA. ICA is an unsupervised statistical technique 
able to identify latent variables called independent components. In the case of Raman micro-
spectroscopy, ICA can be used to identify spectral contributions such as those from substrate, 
using the same number of ICs as PCs, which can then be removed or studied in their own 
right [31, 32]. 
 
2.6. Nuclear condensation:  
Approximately 1 x 10
4
 cells were allowed to attach on uncoated glass bottom Petri dishes 
(MatTek Corporation, USA) for two hours, after which they were covered with cell culture 
medium. After 24hrs incubation, the medium was removed and samples were rinsed twice 
with sterile PBS, after which new fresh medium containing DOX corresponding to the 
inhibitory concentration, IC50, determined by the cytotoxicity assays for each cell line, and 
adjusted to the cell number [29], was added  and cells were incubated for each corresponding 
time point.  
After incubation, old medium was removed and 2mL of Nucred
®
 solution in medium was 
added and, after 15 to 30 min incubation, samples were rinsed twice with sterile PBS and 
kept in PBS for live cell imaging using CLSM. Control samples without exposure to DOX 
were also prepared in parallel, and incubated for 2, 6, 12, 24, 48 and 72hrs. 
CLSM images were recorded using an inverted Zeiss LSM 510 Confocal Laser Scanning 
Microscope equipped with a x60 oil immersion objective. DOX fluorescence was excited 
with an argon ion laser at 488 nm, and the emission was collected at 530 nm, while Nucred
® 
was measured using 633 and 690 nm, excitation and emission, respectively.  
Using ImageJ software, after fluorescence background subtraction, the mean fluorescence 
intensity of Nucred
® 
was measured for 10 cells for each cell line and each time point.  
 
2.7. Bcl-2 protein expression: 
Cells (3x 10
4
/flasks) were cultured in T25 flasks over 24hrs, and then exposed  to a DOX 
dose corresponding to the inhibitory concentration, IC50, adjusted to the cell number [29], 
determined by cytotoxicity assays for each time point (from 2hrs to 72hrs) and each cell line. 
After each incubation period, cells were trypsinised and centrifuged in 5 mL fresh medium at 
4°C and 1100 rpm for 5 min and they were then re-suspended in1mL Ice Cold Dulbecco's 
Phosphate-Buffered Saline (DPBS) buffer and centrifuged at 4°C and 2500 rpm for 5 min. 
Cells were re-suspended in 750 µL ice cold DPBS buffer and transferred to Eppendorf tubes 
to which 250 µL of fixation buffer were added. After 30 min incubation at 4ºC, the fixed cells 
were washed twice in perm/wash buffer, centrifuged (2500 Rpm for 5mn at 4ºC) and then 
gently re-suspended in 50 µL perm/wash buffer, after which 20 µL of the antibody were 
added and the cells were incubated for 60 min in the dark at 4ºC. The cells were then washed 
twice in perm/wash buffer, centrifuged (2500 Rpm for 5mn at 4ºC) to remove unbound 
antibody and finally re-suspended in 1mL stain buffer. 10,000 cells were analysed by Flow 
Cytometry using a BD Biosciences Accuri C6 Flow Cytometer (Becton Dickinson, Oxford, 
UK). The Accuri Flow Cytometry software was used for the analysis of Flow Cytometry 
samples and data processing. 
 
 
 
2.8. γH2AX expression: 
Cells (10
6
/flask) were cultured in T25 flasks over 24h, and then exposed to a DOX dose 
corresponding to the inhibitory concentration, IC50, adjusted to the cell number [29], 
determined by cytotoxicity assays for each time point (from 2hrs to 72hrs) and each cell line. 
After each incubation period, cells were trypsinised and centrifuged in 5 mL fresh medium at 
4°C and 1100 rpm for 5 min, then were re-suspended with 1mL PBS, transferred to an 
Eppendorf tube and centrifuged at 400g for 5mn at 4 ºC. Cells were re-suspended in 200 µL 
of formalin 2% v/v in PBS and incubated for 10mn. If not used immediately, cells can be 
kept in 1mL ice-cold ethanol 70% and samples and stored at -20 ºC for up to two weeks or 
overnight at 4ºC. Cells were then re-suspended in 500 µL Triton X-100 0.25% v/v in PBS 
and incubated at Room Temperature (RT) for 5mn or 30mn at 4ºC, after which cells were 
centrifuged at 400g for 5mn at RT and re-suspend in 200 µL Bovine serum albumin (BSA) 
solution (2mg/100mL) and incubated at RT for 30mn. After centrifugation at 400g for 5mn at 
RT, cells were re-suspended in 150 µL antibody solution diluted in BSA solution 1:500 and 
incubated at RT for 2 hours or overnight at 4ºC. The cells were then washed thrice in PBS 
and finally re-suspended in 1mL BSA solution. 30,000 cells were analysed by Flow 
Cytometry using a BD Biosciences Accuri C6 Flow Cytometer (Becton Dickinson, Oxford, 
UK). The Accuri Flow Cytometry software was used for the analysis of Flow Cytometry 
samples and data processing. 
 
3. Results and discussion: 
3.1. Cytotoxicity assays: 
 
Figure 1 shows the dose dependent responses of the cytotoxicity assays, AB and MTT, for 
early (6-24hrs) and late (48hrs-72hrs) stage to DOX exposure, for both cell lines, A549 and 
Calu-1. Viability is expressed as % compared to control 3 and the error bars indicate the 
standard deviation of six independent replicate measurements in triplicate and repeated three 
times.  
For both in vitro assays and for all exposure times, a partial loss of cell population viability is 
observed for the two cell lines. All viability curves were fitted with Eq.(1) [33] 
V = Vmin + (Vmax - Vmin)/ (1 + (C/IC50)
 n
)   Equation 1 
where V is the % viability, Vmin is the minimum viability, Vmax is the maximum viability, C is 
the DOX concentration, n is the Hill slope, and IC50 is the concentration which elicits 50% of 
the maximum response. . IC50 values are quoted with the error generated from the fit to all 
mean data points. 
 
A1.          A2.
 
B1.          B2. 
 
Figure 1: AB in vitro dose dependent cytotoxicity assays of DOX A1. A549 cell line and A2. 
Calu-1 cell line and MTT in vitro dose dependent cytotoxicity assays of DOX B1. A549 cell 
line and B2. Calu-1cell line. Viability is expressed as % compared to control, and the error 
bars indicate the standard deviation of six independent replicate measurements 
 
The AB and MTT assays for the A549 cell line show similar responses for each time 
exposure (Figure 1 A1 and B1) except for the early stage of 6hrs, at which time point AB 
appears to be less sensitive than MTT. A slightly different profile is observed for the Calu-1 
cell population (Figure 1 A2 and B2), whereby the AB assay is seen to be less sensitive for 
both 6 and 24hrs exposure times. (Table 1) 
  
Table 1: DOX IC50 concentration determined by the AB and MTT assays for the two cell 
lines A549 and Calu-1   
 
 Time (hrs) 6 24 48 72 
IC
5
0
 c
o
n
ce
n
tr
at
io
n
 
(
M
) 
 
A
5
4
9
 AB 
MTT 
1.52±0.20 
1.61±1.43 
0.42 ± 0.06 
0.55 ± 0.16 
0.30± 0.04 
0.31± 0.05 
0.29± 0.02 
0.27± 0.02 
C
al
u
-1
 AB 
MTT 
1.67±0.29 
1.90±0.76 
0.69 ± 0.13 
0.90 ±0.24 
0.62±0.12 
0.72±0.15 
0.37±0.01 
0.41±0.08 
 
 
The AB assay is an expression of general cellular metabolism, while the MTT assay is a 
reflection of mitochondrial activity [17]. Mitochondrial dysfunction is an early effect of DOX 
which explains the difference in the two assays for early exposure time points [34].The 
notably different cytotoxic profiles for the two cell lines, up to 48hrs exposure to DOX, are 
consistent with a higher intrinsic resistance of the Calu-1 cell line to the chemotherapeutic 
drug, whereby Calu-1 cells remain more viable than A549 cells at comparable doses and 
equivalent exposure times.  
The difference in cytotoxicity response between MTT and AB and between the two cell lines 
suggests different contributions of drug mechanisms of action and relatively different cellular 
behaviours to the drug treatment, resulting in a delayed response of Calu-1 cell line compared 
to A549, as indicated by the lower sensitivity of the AB assay up to 24hrs exposure. The 
MTT assay has been widely used as an indicator of chemosensitivity of cancer cell lines to a 
chemotherapeutic drug and shows a good correlation of the in vitro results with clinical 
observations [35-37] and the difference in MTT responses between the two cell lines is 
indicative of a higher chemosensitivity of A549 cells compared to Calu-1. Therefore, the IC50 
concentration determined by MTT assay was used for the rest of experiments. 
 
 
 
 3.2. Raman micro-spectroscopy: 
 
Raman micro-spectroscopy has previously demonstrated that A549 and Calu-1 present 
different sensitivities to DOX treatment after 24hrs exposure as a result of different relative 
contributions of the different mechanisms of action involved [20]. In order to further 
investigate the subcellular differences at early and late stages of exposure, Raman profiles for 
both cell lines were compared after 2, 6, 12, 24, 48 and 72hrs exposure to DOX and spectra 
were taken from the three subcellular compartments, nucleolus, nucleus and cytoplasm (the 
example of original and pre-processed data of Calu-1 24hrs exposure is shown in Figure S1). 
 As previously and for comparibility purposes, the IC50 concentration, as determined by the 
MTT assay, for 24hrs was used for early exposure from 2 to 24hrs and for 48 and 72 hrs, 
each corresponding IC50 concentration was used [29]. 
 
 
Figure 2: A. Pre-processed Raman spectrum of Doxorubicin dissolved in sterile water, and 
loading 1 corresponding to PC1 of PCA of Calu-1 control cells versus Calu-1 2hrs exposure 
of B. nucleolus and C. nucleus   
Multivariate data anlysis, consisting of PCA, PLSR and ICA, was employed in order to 
analyse in more detail the spectral features due to DOX exposure and compare the cellular 
effects and responses between the two cell lines and between the different exposure times.  
A pairwise PCA of exposed cells for each time point versus control for each cellular 
compartment was analysed and separation was observed according to PC1 for all time points. 
As an example PCA of control versus 24hrs exposed for Calu-1 cells is shown in Figure S2. 
Figure 2 shows the loading of PC1 for the nucleus and nucleolus of Calu-1 cells after 2hrs 
exposure, compared to the spectrum of the DOX stock solution. 
As seen in Figure 2, obvious DOX features at 440 and 465 cm
−1
, respectively derived from 
C–C–O and C–O vibrations, and 1085, 1215 and 1245 cm−1, related to C–O–H, C–O and C–
H, are observed in the spectra of the nucleolar, and nuclear regions, highlighting the DOX 
uptake into Calu-1 cells after only 2hrs exposure. 
In both nucleolus and nucleus of Calu-1 cells, features at 1430-1450 cm
-1 
are also observed, 
corresponding to guanine and cytosine (absent in control cells) and are related to DOX-DNA 
intercalation inducing damage and/or conformational changes [15]. The same features have 
been observed after 24hrs of DOX interaction in A549 cells [20] confirming the early stage 
DOX-DNA and RNA binding for both cell lines [38]. The decrease in the bands at 785 and 
813 cm
−1
, corresponding respectively to DNA backbone O–P–O and RNA O–P–O 
phosphodiester bond stretching, confirm an early DOX effect in Calu-1 cells consistent with 
its main mechanism of action, DNA intercalation, interfering with both DNA and RNA 
polymerase, inducing DNA replication and RNA transcription blockage [17, 39]. 
In order to further analyse the DOX cellular kinetics, the DOX peak intensity at 465 cm
-1
, the 
loading of PC1 of each time point and cellular compartment for both cancer cells was 
analysed. This DOX band was chosen due to the minimal influence by the proximity of 
cellular compounds features. Figure 3 shows the time evolution of this band in each 
subcellular region for each cell line.Intensity is expressed in percentage function of the 
highest value observed over all the measurements, that of the A549 nucleolar region after 
6hrs exposure. 
 
Figure 3: Evolution of DOX, represented by the Raman band at 465 cm
-1
, as a function of 
time for the A549 and Calu-1 cell line for each cellular compartment, nucleolus, nucleus and 
cytoplasm. Intensities are expressed as percentage according to the maximum value over the 
three cellular compartments and the two cell lines and standard deviation corresponds to the 
spectral variations of the Raman band over the 30 measurements per location. 
For both cell lines, in each subcellular region, (Figure 3) there is a progressive increase of 
intracellular DOX concentration until a plateau is reached. As previously described for A549 
cells, DOX accumulation is initially observed in the nucleoli, reaching saturation at ~6hrs, 
then in the nucleus, reaching saturation at ~12hrs, before it finally begins to accumulate in the 
cytoplasm, at ~48hrs, after saturation of nuclear binding sites [40, 41]. Notably, the 
subcellular accumulation in Calu-1 is much more rapid, saturating at ~2hrs in the nucleoli, 
~6hrs in the nucleus and is detectable in the cytoplasm after only ~24hrs.  
Despite the fact that DOX-DNA intercalation starts at early stages for both cell lines, 
according to the DOX Raman band, DOX saturation for both nuclear areas happens more 
rapidly in Calu-1 cells than A549, after which DOX concentration inside the combined 
nuclear regions becomes approximately constant and accumulation in the cytoplasm due to 
additional drug taken up by cells is only evident after ~48hrs for A549 and earlier at ~24hrs 
for Calu-1, due, in both cell lines, to nuclear membrane disruption [29]. The saturation levels 
in each subcellular region are comparable for each cell line, although significantly lower 
levels of DOX are recorded in the cytoplasmic region of A549. 
 
A. 
 
B. 
 
Figure 4: A. Loading 1 of PC1 of control versus exposed cells. A. Nucleolus A549 control 
versus 6hrs exposure compared to that of nucleolus Calu-1 control versus 2hrs exposure B. 
Nucleus A549 control versus 12hrs exposure and nucleus Calu-1 control versus 6hrs 
exposure  
 
In order to compare the DOX mechanism of action and cellular responses, cellular features 
were analysed in more detail over the time periods before and after DOX saturation for the 
nuclear and cytoplasmic compartments. 
As seen in Figure 4, which shows the loading of PC1of control cells versus exposed in the 
nuclear regions below the saturation point, almost identical loadings are obtained for both cell 
lines, including dominant DOX peaks at 440, 465, 1215 and 1245 cm
−1
. Guanine and 
cytosine features are prominent, respectively at 1430 and 1450 cm
−1
, confirming DOX 
intercalation and RNA interaction in the nucleolus and DNA in the nuclear region, related to 
DOX binding inducing changes in DNA conformation with a partial transition of DNA from 
B to A form (change in the ratio between 813 cm
−1 
and 830 cm
−1 
bands) and blockage of 
DNA synthesis and as a consequence a decrease in RNA [16, 17]. 
Up to the saturation point, the same spectral features assigned to DOX mechanism of action 
by nuclear intercalation were thus found for A549 and Calu-1, giving a reproducible 
signature of the binding interaction, which appears to be same for the two cell lines. 
In order to track the cellular changes after saturation, PLSR was employed and spectra were 
regressed against time starting from each saturation point 2hrs and 6hrs for Calu-1 cells and 
6hrs and 12hrs for A549 cells, respectively for nucleolus and nucleus. The regression 
coefficients obtained are shown in Figure 5. 
In both cell lines, for the nucleolar regions (Figure 5A), a notable decrease in features at 728 
cm
-1 
(adenine) 785 cm
-1
 (cytosine, thymine and DNA backbone O–P–O), 813 cm-1 (RNA O–
P–O stretching), 1095 cm-1 (DNA PO2
− 
symmetric stretching) and 1376 cm
-1
 (thymine), are 
consistent with a decrease in nucleic acid contributions due to the DOX mechanism of action 
by nucleolar interaction, inducing DNA replication blockage, and decrease of RNA features 
by inhibiting RNA synthesis at the level of rRNA transcription, inhibiting ribosome 
biogenesis, and, as a consequence, alteration of nucleolar structure [42], size, shape and 
fragmentation [17, 20, 29], inducing nucleolar stress dependent apoptosis [43, 44]. 
 
 
 
 
 
A. 
 
B. 
 
Figure 5: Regression coefficients obtained by PLSR analysis as a function of time after DOX 
saturation for A549 and Calu-1 cells for A. nucleolus and B. nucleus.   
 
 
 
The increase in proteins and lipids features at respectively 447-454 cm
-1 
(phenylalanine), 
(those two bands can be detected clearly due to the fact that, after saturation, the DOX 
cellular concentration becomes constant and therefore the peaks of the drug itself are no 
longer evident in the regression), 645-877 cm
-1
 (C-C tyrosine), 940 cm
-1
 (C-C stretching of 
protein) 1207 cm
-1 
(phenylalanine, tryptophan and tyrosine), 1230  cm
-1 
(Amide III), 1520-
1545 cm
-1
 (Amide II) , 1605 cm
-1 
(C=C phenylalanine and tyrosine), 1670 cm
-1 
(Amide I) 
1410-1450 cm
-1
 (CH2 deformation) are consistent with an efflux of anti-apoptotic and repair 
proteins, as a cellular defense against DOX exposure, and a lipid denaturation of the 
surronding cytoplasmic membrane [17, 45]. 
In addition to depletion of spectral features related to DNA in the nuclear area for both cell 
lines, such as those at 795 cm
-1
, 1095 cm
-1 
and 1376 cm
-1  
(Figure 5B), there is an increase in 
both lipid and protein features, at 645 cm
-1
(C-C tyrosine), 715 cm
-1
(choline), 760 cm
-1 
(tryptophan ring breathing), 853-877 cm
-1 
(tyrosine ring breathing), 1127 cm
-1 
(C-N 
stretching), 1445 cm
-1 
(CH2 vibrations), 1491 cm
-1 
(C-H deformation), 1607 cm
-1 
(tyrosine 
and phenylalanine ring vibration C=C), and 1650 cm
-1 
(Amide I), again consistent with a 
cellular response to DOX associated with anti-apoptotic protein and a synthesis of lipidic 
vesicules as a way to remove DOX to the extracellular environment.  
For both the nucleolus and nucleus in A549 cells, a notable increase in features at 1047 cm
-1 
(RNA P–O stretching, sugar phosphate –C–O–stretching), and 1270 cm-1 (RNA Uracil and 
cytosine ring stretching) is due to nucleolar fragmentation, resulting in RNA spread [46].  
The increase in phenylalanine at 1005 cm
-1 
seems to be a marker of the late apoptosis stage, 
at which point nucleolar fragmentation is complete, leaving an empty space with only cellular 
membrane, while in Calu-1 cells and for both nuclear regions, there is an increase in the 1270 
cm
-1 
band and a decrease in the 1047 and 1005 cm
-1 
bands, which could be explained by the 
fact that the nucleolar fragmentation is less advanced in Calu-1 than A549 cells, due to a 
delay in apoptosis by a higher production of anti-apoptotic proteins. In the nucleus of the 
Calu-1 cell line, there is also an increase in some DNA bands at 785 cm
-1 
and 1577 cm
-1
, 
which may be due to an increase DNA repair. 
 
 
 
 
 
 
A. (i)      (ii) 
 
B. (i)       (ii) 
 
Figure 6: A. Evolution of DOX (465 cm
-1
) and selected RNA (785, 813 and 1270 cm
-1
) and 
DNA (728, 785, 813 and 830 cm
-1
) Raman bands as a function of time B. Evolution of DOX 
(465 cm
-1
) and selected protein (645, 1005 and 1250 cm
-1
) and lipid (1450 cm
-1
) Raman 
bands as a function of time for the Calu-1 cell line for each nuclear cellular compartment, (i) 
nucleolus and (ii) nucleus. Intensities are expressed in percentage according to the maximum 
value for each nuclear area and standard deviation corresponds to the spectra variations for 
each band. 
 
In order to highlight the increase of cellular compounds, namely DNA, RNA, proteins and 
lipids in Calu-1 cells, the evolution of related spectral features in both nucleolus and nucleus, 
785 cm
-1
 and 813 cm
-1 (DNA⁄RNA), 728 cm-1 and 830 cm-1 (DNA), 645 cm-1, 1005 cm-1 and 
1250 cm
-1 
(proteins) and 1450 cm
-1 
(lipids), as a function of time can be plotted (Figure 6). 
The band intensities were determined by ICA after DOX substraction. The DOX band was 
determined, as Figure 3, by PCA control vs exposed cells. The evolution of similar bands in 
A549 cells has been demonstrated previously [29]. 
A notable decrease in DNA and RNA features is observed (Figure 6 A(i) and A(ii)) at the 
early stage, concomitant with DOX nuclear accumulation and binding, due to DNA⁄RNA 
alteration, followed by an increase in the same features starting from ~24hrs, as a cellular 
response by increasing DNA repair. However, the changes appear to be slower in the nucleus 
and much stronger in the nucleolus, in which a decrease of nucleic acids to less than 10% is 
observed, after which they increase to almost the same proportion ~ 40%. The decrease in 
nucleic acid features appears also to be stronger in Calu-1 compared to A549 [29]. After 
DOX saturation, ~2hrs for the nucleolus and ~6hrs for the nucleus, proteins and lipids start 
increasing (Figure 6 B(i) and B(ii)), consistent with the production of anti-apoptitic proteins 
and a synthesis of lipidic vesicules inducing resistance to apoptosis and as a consequence 
resistance to the chemotherapeutic drug.  
In both nucleolar and nuclear regions, similar kinetics of cellular compounds were found for 
the two cell lines [29] at the early stages, resulting in a decrease of all cellular features, and 
after DOX nuclear saturation an increase of protein and lipids is observed, while nucleic 
features keep decreasing for A549, in contrast to Calu-1 cells which, at prolonged exposures, 
show signs of recovery by DNA repair, resulting in an increase of nucleic acids features. 
In both PLSR regression co-efficient profiles for the cytoplasmic region, for the two cell 
lines, as shown in Figure 7, there are obvious DOX features at 440-465 cm
-1
 and 1215-1245 
cm
-1
. An increase in protein and lipid features is also evident, for example at 524-733 cm
-1
, 
corresponding to phosphatidylserine externalization (in healthy cells, aminophospholipids are 
localised in the inner cytoplasmic membrane) due to membrane alteration [47, 48] as an 
indicator of apoptosis [49, 50], 538 cm
-1
 (cholesterol ester), related to alteration of 
endoplasmic reticulum membrane as a marker of apoptosis [29], 576-720 cm
-1 
(phosphatidylinositol and phosphatidylcholine) related to membrane trafficking, 645-830-853 
cm
-1
 (tyrosine), 1268 cm
-1
 (Amide III), 1364 cm
-1
 (tryptophan), 1410-1450 cm
-1
 (CH2 
deformation) and 1635-1660 cm
-1
 (Amide I of different conformational forms) indicating a 
protein and lipid denaturation due to DOX treatment. 
 
 
 
 
 Figure 7: Regression coefficients obtained by PLSR analysis as a function of time over full 
range of cytoplasmic region  for A549 and Calu-1 cells  
In addition to the common protein and lipid denaturation indicators between the two cell 
lines, there is a more notable increase in Calu-1 cells of the bands at 917 cm
-1
 (Ribose 
vibration) [51], 940 cm
-1
 (C-C stretching of protein), 1030 cm
-1 
(C-H phenylalanine), 1047 
cm
-1 
(RNA P–O stretching, sugar phosphate –C–O–stretching) and 1085 and 1128 cm-1 (C-N 
stretching) corresponding to higher RNA, protein and lipids structure denaturation by 
oxidative stress due to ROS production, one of the DOX mechanisms of action which has 
previously been shown to be more prominent in Calu-1 than A549 cells [13, 20]. 
Therefore, according to the Raman profile, for the two cell lines, DOX appears to have the 
same binding signatures as seen in loading 1 of PC1 of PCA of control versus exposed cells 
up to saturation point (Figure 4), but Calu-1cells,despite an earlier DOX cellular 
accumulation (Figure 3), seem to be more resistant, as indicated by the lower cytotoxic 
response, due to an efflux of anti-apoptotic protein and an increased DNA repair at the later 
stages. In order to confirm those observations, bcl-2, an anti-apoptotic protein, and γH2AX, a 
marker of DNA damage and repair, were measured in both cell lines and the results were 
correlated to the Raman analysis. 
 
 
 
3.3. Apoptosis, Bcl-2 protein and DNA repair: 
Apoptosis is a programmed caspase-mediated cell death characterised by morphological 
cellular changes, including nuclear and cytoplasmic condensation with externalisation of 
phosphatidylserine and formation of apoptotic bodies, with maintenance of intact cellular 
membrane. During the later stages, the nucleus further condenses (pyknosis), which is the 
most characteristic morphological marker of apoptosis, [52, 53] and this is followed by 
nuclear shrinkage (karyorrhexis) and loss of cellular shape by cytoskeleton cleavage and 
membrane blebbing [54, 55]. 
Figure 8 shows the evolution of Nucred
®
 fluorescence, as an indicator of nuclear 
condensation, as a function of time for the two cell lines. In both cases, there is a slight 
increase in fluorescence in the early stages of drug exposure, and the maximum fluorescence 
is observed at 24hrs. The maximum is significantly higher for Calu-1 than A549, due to a 
higher level of chromatin condensation induced by DNA damage due to DOX-DNA 
interaction [15], confirming the Raman observations (Figure 6). 
 
 
 
Figure 8: Mean Fluorescence of Nucred
® 
after DOX exposure measured by Confocal Laser 
Scanning Microscopy and ImageJ for A549 and Calu-1 cells, expressed on percentage 
according to the maximum value for both cell lines. 
 
Subsequently, the fluorescence decreases more rapidly in A549 than Calu-1, as a 
consequence of a higher apoptotic response in Calu-1, via chromatin condensation, [56] 
confirming the Raman results showing that the two cell lines have the same behaviour at 
early stages but are different in the later stages. Despite the fact that DOX saturates the 
nuclear area earlier in Calu-1 than A549, and exhibits higher DNA damage levels, Calu-1 
cells appear to be more viable at later stages, which suggest a more effective defence 
mechanism in Calu-1, increasing cell survival [57, 58], and as a consequence a higher 
resistance to DOX. 
This drug resistance could be explained by either a higher expression of anti-apoptotic 
protein or an increase in DNA repair, or both. 
The expression profile of bcl-2 (B cell lymphoma) an anti-apoptotic protein synthesized as a 
direct response to DNA damage, [20] as a function of time for the two cell lines is shown in 
Figure 9. A similar profile is observed, with up regulation followed by a diminution of the 
bcl-2 protein level as a function of time. Nevertheless, the maximum level of bcl-2 is reached 
at 12hrs in the A549 cell line and 48hrs in Calu-1, with an obviously consistently higher 
expression for the later stage over the time range. This higher level of bcl-2 protein 
contributes to cellular resistance to apoptosis inducing a chemotherapeutic drug resistance.  
 
 
Figure 9: Bcl-2 anti-apoptotic protein level determined by Flow Cytometry after DOX 
exposure from time point 2 to 72hrs for A549 and Calu-1 cells, expressed on percentage 
according to the maximum value for both cell lines. 
 
A specific change in response to DSB is the phosphorylation of H2AX histone, representing 
2 to 25% of the total H2A protein, by members of phosphoinositide 3-kinase related proteins 
of DDR, into γH2AX a sensitive indicator of DSB and efficiency of subsequent DNA repair 
[24, 59, 60], which is facilated by γH2AX dephosphorylation by protein phosphatase 2A [26, 
61]. The phosphorylation of γH2AX is thus an early indicator of DSB [53, 62] and the 
number of γH2AX nuclear foci is directly correlated with the number of DSBs, [63] which 
means the more damage there is, the more nuclear foci will be found. Flow Cytometry is a 
sensitive and rapid technique for the measurement of γH2AX phosphorylation at cellular 
level [64]. 
As seen in Figure 10, showing the γH2AX expression after DOX exposure for each time 
point for the two cell lines, there is a progressive increase of γH2AX until a maximum is 
reached, followed by a later decrease for the two cell lines. However, for Calu-1, an obvious 
higher phosphorylation is observed for early stages explained by a higher DNA damage, as 
observed in the Nucred
®
 (Figure 8) and Raman results (Figure 6) and the maximum 
expression is observed at 12hrs, while for A549 it is observed at 24hrs, consistent with a 
more rapid uptake of the drug in the nuclear regions of Calu-1. After the 12 hrs maximum, 
the γH2AX levels are seen to decrease more rapidly for the Calu-1 cells than observed for the 
A549. The decrease in γH2AX corresponds to dephosphorylation of this histone after DNA 
repair and this dephosphorylation is proportional to DNA repair mechanisms which occur 
over time to repair the DNA damage. In this case, it appears that there is an increased 
tolerance to DNA damage and a higher degree of DNA repair in Calu-1 cells than in A549, 
confirming the Raman observations (Figure 5 and 6) showing a recovery in DNA features for 
Calu-1 at the later stages inducing a delay and resistance to apoptosis. 
 
 
 Figure 10: Mean Fluorescence of γH2AX after DOX exposure measured by Flow Cytometry 
for A549 and Calu-1 cells, expressed on percentage according to the maximum value for both 
cell lines. 
 
Raman micro spectroscopic results elucidate both drug kinetics and mechanism of action, 
giving a fingerprint of chemical binding, nucleic acid intercalation, and signatures of cellular 
resistance associated with tolerance to DNA damage, synthesis of anti-apoptotic protein and 
DNA repair. Multivariate data analysis (PCA, ICA and PLSR) indicates that the two cell lines 
have different rates of uptake, resulting in earlier saturation of both nucleolar and nuclear 
compartments for the Calu-1 cell line, and an earlier appearance of DOX in cytoplasm due to 
nuclear disruption.  
It has been reported that cellular uptake of the weakly-basic drug DOX is dependent on the 
extracellular pH [65], and thus, the lower pH of the DMEM-F12 (pH 7-7.4) compared to that 
of RPMI (pH 8.2 ± 0.3) may be the cause of a slower uptake of DOX in A549 cells compared 
to Calu-1. However, the degree of accumulation in the nulei and nucleoli is seen to be similar 
in the two cell lines, indicating that there are no intracellular pH dependent differences 
between the cell lines [65]. After passive diffusion through the cellular cytoplasmic 
membrane due to its high lipophilicity, DOX binds directly to proteasomal transporters and 
translocates into the combined nuclear area whereupon it binds to nucleic acids and rapidly 
saturates the nucleolar region [29]. Cellular efflux regulators can also impact on the rate of 
accumulation in the cell nucleus [66], although the enhanced DOX cellular uptake observed 
in Calu-1 compared to A549 cells should be associated with higher cytotoxicity in Calu-1 
cells [67]. The fact that the inverse is observed is a strong indication that the cellular 
resistance has origin in higher tolerance to DNA damage with higher synthesis of anti-
apoptotic proteins. 
Critically, the early signatures of interactin of the drug, associated with the drug interaction, 
are comparable in the two cell lines, indicating that the methodology can be developed for 
label free, prescreening of drug candidates in vitro. 
Regression against time after DOX saturation in the respective nuclear regions shows 
essentially the subsequent cellular responses to DOX exposure, including DNA⁄RNA damage 
leading to apoptosis and the different cellular reactions such as synthetis of lipidic vesicules 
and increase in protien features. Despite the fact that same binding signature was found for 
the two cell lines, Calu-1 cells show higher resistance, correlated with notably different dose 
dependent cytotoxic response profiles, suggesting a higher viability, firstly by increased 
tolerence to DNA damage manifest as a decrease of DNA to ~10% of control compared to 
40% in A549, confirmed by higher nuclear condensation according to the Nucred
®
 assay, and 
larger amount of γH2AX at early exposure points and secondly, higher expression of anti-
apoptotic proteins, principaly bcl-2 one and higher DNA repair, confirmed by H2AX 
dephosphorylation at later stages.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Conclusion:  
 
Raman micro-spectroscopy has already demonstrated its potential to track in vitro the kinetics 
and accumulation of the chemotherapeutic drug DOX at a subcellular level and to identify its 
different mechanism of action [17, 20, 29]. The present study not only confirms its ability to 
monitor drug cellular kinetics and mechanism of action but also to differentiate between 
cellular reactions and resistance. In fact, the two lung cell lines exhibit different behaviours 
with higher nuclear condensation, measured by Nucred
®
, and a higher resistance of Calu-1, 
despite the similar drug chemical binding, with a higher tolerance to DNA damage and 
implications of DNA repair mechanism confirmed by expression of γH2AX protein, and 
resistance to apoptosis by bcl-2 protein expression. 
Thus, Raman micro-spectroscopy is able not only to track the subcellular accumulation of the 
drug as function of time but also to identify its mechanism of action, the subsequent cellular 
response and to differentiate cellular resistance. Therefore, it can be used as an in vitro, pre-
clinical screening technique for drug mechanism of action and efficacy in order to aid 
preclinical drug development. Furthermore, the ability of Raman micro-spectroscopy to 
monitor subcellular processes associated with drug resistances suggests its potential as an in 
vitro companion diagnostics technique to screen for personalised therapies. 
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Graphical Abstract: 
 
Raman micro-spectroscopy is employed to investigate and compare Doxorubicin mechanisms 
of action, its kinetics and different cellular resistances of cancer cell lines A549 and Calu-1. 
Results show the potential of Raman not only to distinguish the different mechanisms of 
action at subcellular level but also to elucidate drug resistance by increase tolerance to DNA 
damage and higher DNA repair. 
 
 
